Work

Successful venom immunotherapy in a child with anaphylaxis to Hymenoptera skin testing

Year: 2025

Type: article

Abstract: Omalizumab has been used during venom immunotherapy primarily for high-risk adult patients. We report a similar approach in a child with anaphylaxis in response to Hymenoptera skin testing who successfully tolerated modified rush venom immunotherapy with concurrent use of omalizumab.

Source: Journal of Allergy and Clinical Immunology Global

DOI: 10.1016/j.jacig.2025.100619

Authors: Ellen Conroy, Mandi Bailey, Jackie Garrett, Ana Broyles

Institutions: Boston Children's Hospital, Harvard University, Amherst College

Language: English

Topic: Food Allergy and Anaphylaxis Research

Subfield: Immunology and Allergy

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,000